AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.82 |
Market Cap | 87.54M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.58 |
PE Ratio (ttm) | -1.15 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.84 |
Volume | 20,148 |
Avg. Volume (20D) | 374,900 |
Open | 1.82 |
Previous Close | 1.79 |
Day's Range | 1.82 - 1.83 |
52-Week Range | 1.74 - 14.50 |
Beta | undefined |
About GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform ...
Analyst Forecast
According to 2 analyst ratings, the average rating for GUTS stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 889.01% from the latest price.